Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The relationship between monopausal estrogen treatment and endometrial cancer is discussed. One must consider the facultative co-carinogeninity of certain hormones. In lower dosages they may have a terrain effect or unspecific permissive effect on the development of cancer, yet when used in high dosages, e.g. estriol, they can inhibit cancer growth. There are also many predisposing factors to developing cancer which should be taken into consideration when interpreting research results. Although American studies have shown a relationship between therapeutic menopausal estrogen treatment and endometrial cancer, European studies indicate that there is no increased risk if certain guidelines are followed. These include: cyclical treatment, lowest possible hormone dosages, use of gestagen, use of estriol where possible, and consideration of predisposing factors. These guidelines were not followed in the U.S. studies.
Fortschr Med 1978 Dec 01
PMID:[Estrogens and endometrial carcinoma. Position paper on the publication of the drug commission]. 3 20

The concensus conclusions reached at a concensus development conference on Estrogen Use and Postmenopausal Women in September 1979 are based on 3 position papers prepared for the conference, the response of the panel, and the general discussion by the audience, followed by the panel and other conference participants. The evidence for the efficacy of estrogens in treating specific conditions associated with menopause was reviewed 1st. It was accepted that estrogens are more effective than placebo in decreasing the frequency and severity of vasomotor symptoms. Estrogens are effective in overcoming the atrophy of the vaginal epithelium and the associated symptoms. Present evidence does not justify the use of estrogens to treat primary psychological problems. The validity of 3 randomized trials indicating that exogenous estrogens can retard bone loss if given around the time of menopause was acknowledged. There is no convincing evidence that estrogens in customary doses increase the risk of thromboembolic phenomena, stroke, or heart disease in women who have undergone natural menopause. Evidence was also reviewed concerning adverse effects associated with post-menopausal estrogen use. In the absence of exogenous estrogens, the incidence of endometrial cancer is about 1/1000 postmenopausal women per year. This rate increases severalfold beginning after about 2-4 years of use of 0.625 or 1.25 mg of conjugated estrogens daily. Cystic hyperplasia of the endometrium, regarded as a premalignant condition, has been associated with unopposed estrogen, whether endogenous or exogenous.
Ann Intern Med 1979 Dec
PMID:Estrogen use and postmenopausal women: a National Institutes of Health Consensus Development Conference. 4 37

The possibility that the use of conjugated estrogens increases the risk of endometrial carcinoma was investigated in patients and a twofold age-matched control series from the same population. Conjugated estrogens (principally sodium estrone sulfate) use was recorded for 57 per cent of 94 patients with endometrial carcinoma, and for 15 per cent of controls. The corresponding point estimate of the (instantaneous) risk ratio was 7.6 with a one-sided 95 per cent lower confidence limit of 4.7. The risk-ratio estimate increased with duration of exposure: from 5.6 for 1 to 4.9 years exposure to 13.9 for seven or more years. The estimated proportion of cases related to conjugated estrogens, the etiologic fraction, was 50 per cent with a one-sided 95 per cent lower confidence limit of 41 per cent. These data suggest that conjugated estrogens have an etiologic role in endometrial carcinoma.
N Engl J Med 1975 Dec 04
PMID:Increased risk of endometrial carcinoma among users of conjugated estrogens. 17 69

Inhibition of migration of leukocytes from patients with serous cystadenocarcinoma of the ovary was studied by the use of several different types of ovarian carcinoma extract as antigen. KCl extract of an ovarian carconoma was found to be the most effective antigen preparation in comparison with saline, deoxycholate, and perchloric acid extracts. Low concentrations of KCl ovarian carcinoma extract significantly inhibited migration of leukocytes from 11 of 17 patients with ovarian carcinoma (migration index, less than 0.74). Leukocytes from patients with breast, colon, or endometrial carcinoma showed minimal reactivity with ovarian carcinoma KCl extract, and leukocytes from patients with ovarian carcinoma showed minimal reactivity with KCl extracts of breast, colon, and endometrial carcinoma. These results suggested that the 3 M KCl procedure is superior for the isolation of antigens active in the leukocyte migration inhibition test and that this test may be of use for the isolation of tumor-associated antigen and the immunodiagnosis of ovarian carcinoma.
J Natl Cancer Inst 1977 Dec
PMID:Leukocyte migration in ovarian carcinoma: comparison of inhibitory activity of tumor extracts. 20 Jul 54

A review of the nature of estrogens (Es) and their effects on the female genital tract, the effects of deprivation in the climacteric, and treatment of menopausal women is presented. The production of E begins in significant amounts in puberty. It is necessary for growth and development, secondary sex characteristics, and maintenance of pregnancy. Specific structural and metabolic alterations produced by E deficiency are described. Symptoms of the climacteric and postmenopause vary widely in severity. Familial, cultural,and educational background are important aspects of symptom development as is the psychological status of the woman. The role of E in the etiology of endometrial cancer is still unclear although some relationship is suggested. A description of therapy includes dose and administration and surveillance. There must be positive indication for the use of E and constant follow-up must be included.
Clin Obstet Gynecol 1977 Dec
PMID:Use of estrogens in the climacteric and postmenopausal years. 34 68

In women with gynecologic malignancies the para-aortic lymph nodes are not routinely treated. However, pretherapy surgical staging has now disclosed an incidence of para-aortic node metastasis of 10.3% for presumed stage I and II ovarian cancer, 8.0% for stage I endometrial carcinoma, and 23.5% for stage II, III, and IV cervical cancer. Prospective trials to evaluate therapy directed to the para-aortic nodes in women with early ovarian and endometrial carcinoma have not been carried out. Moreover, the results of high dose irradiation to biopsy proven metastasis to the aortic lymph nodes from cervical cancer has resulted in only 11.9% survival without recurrence at two years.
J Surg Oncol 1979 Dec
PMID:Para-aortic node biopsy in staging women with cervical, ovarian and endometrial carcinoma: a review. 39 98

This lengthy discussion of possible associations between both endogenous and exogenous estrogens and progestins to occurrence of human cancers begins by discussing endogenous metabolism of the 2 sex steroid types. For example, the endogenous production of estrogen is associated with anovulation and endometrial cancer, although clearly other risk factors are associated with these diseases, and breast cancer, which account for some or all of the sex hormones apparent carcinogenic effect. Also discussed are the modulating effects of estriol on response of the breast and endometrium to estradiol and estrogens, and the modulating effects of androgens on development of breast cancer. The bulk of the monograph concerns summaries of data on the correlations of exogenous sex hormones and human cancers. Attention is also paid to the use of exogenous sex hormones for treatments of human cancers. Estrogens have been used to treat endometrial cancer, breast cancer, and benign breast disease. Side effects of hormonal contraception discussed include gross and microscopic changes in the breast, benign breast disease, and breast cancer; in the uterus, exogenous hormonal contraception is associated with neoplastic changes in the cervix, cervical neoplasia, endometrial cancer, trophoblastic tumors, and uterine fibroids. Ovarian effects include nonneoplastic and benign lesions and ovarian cancers. Oral contraception may also correlate with incidences of pituitary and melanoma malignancies. Liver effects include both benign neoplasms and malignant tumors.
IARC Monogr Eval Carcinog Risk Chem Hum 1979 Dec
PMID:Oestrogens and progestins in relation to human cancer. 39 83

For many years, a variety of abnormal endometrial lesions have been linked to endometrial cancer but have been designated as hyperplasia and classified by modifying adjectives such as cystic, adenomatous, atypical, moderate, and severe. Though descriptively distinctive, there are enough consistent histologic transitions between them to designate the entire group as belonging to a continuous spectrum from benign to malignant. Furthermore, because these epithelial lesions demonstrate not just hyperplasia but significant disorderly growth patterns, it has been suggested that they be referred to as dysplasias. In order to evaluate the association of these types of dysplasia to cancer, two groups of patients were studied. In one group, the histologic states of the endometrium of patients with endometrial cancer were retrospectively analyzed. In the second group of patients, who were selected for study because the endometria were diagnosed as belonging to the dysplastic groups, the subsequent endometrial histology was prospectively studied. The findings suggest that there is a recognizable group of endometrial lesions with an association to endometrial cancer strong enought to label and treat them as neoplastic.
Am J Obstet Gynecol 1979 Dec 01
PMID:The precursors of endometrial carcinoma. 50 34

Despite reports of studies linking menopausal estrogen therapy with endometrial cancer in 1975, physicians have persisted in considering menopause a condition needing medication--with estrogens. To assess the risks and benefits, NIH held a conference on estrogen usage in postmenopausal women. A panel of physicians heard the therapeutic, epidemiologic, and sociologic evidence and summarized the findings in a final report. It was agreed that estrogen therapy will be effective in combating vasomotor flushes (hot flashes) and vaginal atrophy and dryness. Evidence to justify estrogen use for coronary vascular disease and depression does not exist. Further evidence is needed to deterine whether estrogen therapy will decrease osteoporosis-related fractures. The risk of endometrial cancer increases 4-8-fold following 2-4 years of continuous estrogen usage. It was concluded that estrogens should be prescribed in the lowest effective dosages and for short terms, not exceedng 2-4 years. Cyclic progestin administration and yearly curettage sampling for endometrial cancer might reduce the risk of developing endometrial cancer while on estrogen therapy.
Am J Hosp Pharm 1979 Dec
PMID:Estrogen prescribing practices scrutinized at NIH conference. 52 51

The official mortality statistics in Austria fail to report the localization of uterine cancer in nearly two thirds of cases and, thus, the annual death rate of women with cervical versus endometrial cancer is not clear. These two diseases behave totally differently with regard to their aetiology, age distribution, early diagnosis, therapy and prognosis and, therefore, a separate analysis is necessary. This study presents an analysis of the incidence of uterine cancer in a series of 7,276 women who died in Vienna hospitals in 1976. Of the 151 cases (2% of all the women in the examined collective) 106 died of cervical carcinoma, 33 of endometrial carcinoma and 9 of unspecified uterine carcinoma. The average age of women who died of cervical carcinomas was 60 years, whilst that of patients with endometrial carcinoma was 71.7 years. In 12.6% of cases double carcinomata were found. The relation between deaths from cervical carcinoma to endometrial carcinoma is 3.3:1. If this ratio is applied to the 942 deaths from uterine carcinoma in 1976 in Austria, then one can estimate that more than 700 women must have died of cervical carcinoma and more than 200 of endometrial carcinoma. The 303 deaths from cervical carcinoma and 65 from endometrial carcinoma reported in the official mortality statistics are, therefore, totally misleading and ought not to be used as a basis for epidemiological investigations.
Wien Klin Wochenschr 1979 Dec 07
PMID:[Carcinoma of the uterus in the Austrian mortality statistics. 1. Carcinoma of the uterus in Viennese autopsy reports 1976 (author's transl)]. 53 32


1 2 3 4 5 6 7 8 9 10 Next >>